A Phase I, Single-Centre, Double-Blind, Placebo-Controlled, Escalating Single Oral Dose, Safety and Tolerability Clinical Trial With BTA9881 in Healthy Subjects

Trial Profile

A Phase I, Single-Centre, Double-Blind, Placebo-Controlled, Escalating Single Oral Dose, Safety and Tolerability Clinical Trial With BTA9881 in Healthy Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 08 Apr 2015

At a glance

  • Drugs BTA 9881 (Primary)
  • Indications Respiratory syncytial virus infections
  • Focus Adverse reactions
  • Sponsors Biota Pharmaceuticals
  • Most Recent Events

    • 16 Oct 2009 Actual end date (Dec 2008) added as reported by ClinicalTrials.gov.
    • 16 Oct 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 23 Jan 2008 The expected completion date for this trial is now 1 May 2008 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top